X0206 3 2021-10-07 0 0001782223 Pyxis Oncology, Inc. PYXO 0001820027 Bayer World Investments B.V. ENERGIEWEG 1 MIJDRECHT P7 3641RT NETHERLANDS 0 0 1 0 0001144145 BAYER AKTIENGESELLSCHAFT BAYERWERK, GEBAEUDE W11 KAISER-WILHELM-ALLEE 1 LEVERKUSEN 2M 51373 GERMANY 0 0 1 0 Series A Convertible Preferred Stock Common Stock 1786831 D Series B Convertible Preferred Stock Common Stock 955507 D Shares of Series A and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") have no expiration date and, as of the date of this filing, are convertible, at the option of the Reporting Persons, into shares of the Issuer's common stock at a 6.359-for-1 conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares). Reflects that each 6.359 shares of Preferred Stock will convert automatically into one share of the Issuer's common stock at the closing of the Issuer's initial public offering, for no additional consideration (subject to the payment of cash in lieu of any fractional shares). The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Bayer World Investments B.V., By: /s/ Patrick Lennaerts, Name: Patrick Lennaerts, Title: Managing Director 2021-10-07 Bayer Aktiengesellschaft, By: /s/ Christian Bank, Name: Christian Bank, Title: Head of Legal Mergers & Acquisitions 2021-10-07